AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28449051 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilpivirine (RPV)
Number of subjects: 60
Study 28449051 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat-boosted elvitegravir (EVGcobi)
Number of subjects: 60
Study 28449051 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted darunavir (DRVrtv)
Number of subjects: 60
Study 25317575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask A (Quattro®)
Number of subjects: 17
Study 25317575 — intervention group
Group type: COMPARATOR
Intervention: Mask B (Amara®)
Number of subjects: 17
Study 25317575 — intervention group
Group type: EXPERIMENTAL
Intervention: Mask C (Forma®)
Number of subjects: 17
Study 23296097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus modified-release once-daily preparation (Advagraf, Graceptor)
Number of subjects: 43
Study 21459255 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Doctor counseling
Number of subjects: 321
Study 21459255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 321
Study 21459255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 321
Study 18268150 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning (repeated inflation and deflation of the angioplasty balloon)
Number of subjects: 38
Study 18268150 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 38
Study 18268150 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 38
Study 18268150 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study 16537980 — intervention group
Group type: EXPERIMENTAL
Intervention: Leg-segmental method
Number of subjects: 100
Study 16537980 — intervention group
Group type: COMPARATOR
Intervention: Global method
Number of subjects: 100
Study 14723748 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐8815Ly at 4 microg/minute
Number of subjects: 17
Study 14723748 — intervention group
Group type: EXPERIMENTAL
Intervention: ONO‐8815Ly at 8 microg/minute
Number of subjects: 17
Study 14723748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 11725927 — intervention group
Group type: EXPERIMENTAL
Intervention: Simes‐Hommel intersection‐union tests
Number of subjects: 0
Study 11725927 — intervention group
Group type: EXPERIMENTAL
Intervention: Resampling‐Based methods
Number of subjects: 0
Study 11725927 — intervention group
Group type: COMPARATOR
Intervention: Bonferroni‐Holm
Number of subjects: 0
Study 10322833 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemented Sini San (SSNS)
Number of subjects: 127
Study 10322833 — intervention group
Group type: COMPARATOR
Intervention: Dioscorea Nipponica Power (Control)
Number of subjects: 127
Study 8489354 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG)
Number of subjects: 66
Study 8489354 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 66
Study 2942806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol/ipratropium combination (100 micrograms fenoterol and 40 micrograms ipratropium bromide per puff, 2 puffs)
Number of subjects: 10
Study 2942806 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (100 micrograms per puff, 2 puffs)
Number of subjects: 10
Study 27458105 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (0.6 ng/kg)
Number of subjects: 172
Study 27458105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 28007133 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg once daily for 5 years
Number of subjects: 3318
Study 28007133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3318
Study 25876338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of acupuncture and tapping method
Number of subjects: 104
Study 25876338 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 104
Study 21557265 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (ASE)
Number of subjects: 0
Study 21557265 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethylasenapine (DMA)
Number of subjects: 0
Study 21557265 — intervention group
Group type: EXPERIMENTAL
Intervention: 11-O-sulfate-asenapine (OSA)
Number of subjects: 0
Study 21557265 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine-N(+) -glucuronide (ASG)
Number of subjects: 0
Study 20536517 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes Care Protocol (DCP)
Number of subjects: 3389
Study 20536517 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 3389
Study 19856616 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site plus peer-led support group
Number of subjects: 21
Study 19856616 — intervention group
Group type: COMPARATOR
Intervention: Web site only
Number of subjects: 21
Study 19856616 — intervention group
Group type: EXPERIMENTAL
Intervention: Web site only and Web site plus peer-led support group
Number of subjects: 21
Study 12166461 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trial (RCT)
Number of subjects: 0
Study 9581367 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral vented titanium post
Number of subjects: 30
Study 9581367 — intervention group
Group type: COMPARATOR
Intervention: Spiral serrated, hollow stainless steel post
Number of subjects: 30
Study 9581367 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral hollow stainless steel post
Number of subjects: 30
Study 8139605 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete vision
Number of subjects: 0
Study 8139605 — intervention group
Group type: EXPERIMENTAL
Intervention: Vision of the target occluded
Number of subjects: 0
Study 8139605 — intervention group
Group type: EXPERIMENTAL
Intervention: No vision of the moving hand
Number of subjects: 0
Study 8139605 — intervention group
Group type: EXPERIMENTAL
Intervention: No visual feedback (both target and hand occluded)
Number of subjects: 0
Study 8139605 — intervention group
Group type: COMPARATOR
Intervention: Visual feedback (any condition)
Number of subjects: 0
Study 3293872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyramine administered by bolus injection
Number of subjects: 12
Study 3293872 — intervention group
Group type: COMPARATOR
Intervention: Tyramine administered by infusion
Number of subjects: 12
Study 31935778 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training program (15 sessions of four eccentric exercises)
Number of subjects: 27
Study 31935778 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study 31445956 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Gy in 1 fraction (arm 1)
Number of subjects: 98
Study 31445956 — intervention group
Group type: COMPARATOR
Intervention: 60 Gy in 3 fractions (arm 2)
Number of subjects: 98
Study 28220486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan (Cmab + I)
Number of subjects: 1081
Study 28220486 — intervention group
Group type: COMPARATOR
Intervention: Panitumumab (Pmab)
Number of subjects: 1081
Study 28220486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 1081
Study 25332252 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50-based risk of recurrence (ROR) score
Number of subjects: 2137
Study 25332252 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Treatment Score (CTS)
Number of subjects: 2137
Study 23758078 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus weekly/biweekly teleconsultations with an endocrinologist (n=12)
Number of subjects: 23
Study 23758078 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control; n=11)
Number of subjects: 23
Study 23758078 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus teleconsultations (n=12)
Number of subjects: 23
Study 21478777 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered cognitive behavioral therapy (CBT) plus pedometer-based walking program
Number of subjects: 291
Study 21478777 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 291
Study 18855558 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadjuvanted RSV vaccine
Number of subjects: 1169
Study 18855558 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvanted RSV vaccine
Number of subjects: 1169
Study 18855558 — intervention group
Group type: COMPARATOR
Intervention: RSV vaccine (both formulations)
Number of subjects: 1169
Study 18855558 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine
Number of subjects: 1169
Study 16861098 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol 30 mg/kg IV
Number of subjects: 41
Study 16861098 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 12911355 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use bougie
Number of subjects: 64
Study 12911355 — intervention group
Group type: COMPARATOR
Intervention: Oral flexible intubating fibrescope
Number of subjects: 64
Study 12911355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 64
Study 10787581 — intervention group
Group type: EXPERIMENTAL
Intervention: Process variables in primary care
Number of subjects: 0
Study 10787581 — intervention group
Group type: EXPERIMENTAL
Intervention: Process variables in secondary care
Number of subjects: 0
Study 10787581 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient outcomes in primary care
Number of subjects: 0
Study 9233368 — intervention group
Group type: EXPERIMENTAL
Intervention: Faded bedtime with response cost (FBRC)
Number of subjects: 2
Study 9233368 — intervention group
Group type: COMPARATOR
Intervention: Bedtime scheduling procedure
Number of subjects: 2
Study 8130009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-heparin (Sandoparin)
Number of subjects: 68
Study 8130009 — intervention group
Group type: COMPARATOR
Intervention: Standard-heparin (Liquemin: 3 x 5000 I.E.)
Number of subjects: 68
Study 8130009 — intervention group
Group type: COMPARATOR
Intervention: Standard-heparin
Number of subjects: 68
Study 8130009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-heparin
Number of subjects: 68
Study 8130009 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid Crystal Contact Thermography (LCCT)
Number of subjects: 68
Study 8130009 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 68
Study 30239830 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent type 3 OPV
Number of subjects: 240
Study 29560311 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 μg LSD
Number of subjects: 20
Study 29560311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 26371766 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser (PDL)
Number of subjects: 22
Study 26371766 — intervention group
Group type: EXPERIMENTAL
Intervention: Long pulsed Nd:YAG laser
Number of subjects: 22
Study 24128648 — intervention group
Group type: EXPERIMENTAL
Intervention: Infecting strain from cases
Number of subjects: 163
Study 24128648 — intervention group
Group type: COMPARATOR
Intervention: Household contacts with colonizing strain
Number of subjects: 163
Study 24128648 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall strain types identified
Number of subjects: 163
Study 24128648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrafamilial strain-relatedness
Number of subjects: 163
Study 24128648 — intervention group
Group type: EXPERIMENTAL
Intervention: Cases with discordant strains
Number of subjects: 163
Study 22362335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest SPECT MPI
Number of subjects: 294
Study 20117912 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.1 mg (group M)
Number of subjects: 66
Study 20117912 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 66
Study 17936643 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg caffeine
Number of subjects: 15
Study 17936643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 16918590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg, intravenously)
Number of subjects: 6
Study 16918590 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin plus GHRH (1 microg/kg, iv)
Number of subjects: 6
Study 16918590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12848832 — intervention group
Group type: EXPERIMENTAL
Intervention: Workbook-Journal (WBJ) intervention plus educational materials
Number of subjects: 100
Study 12848832 — intervention group
Group type: COMPARATOR
Intervention: Educational materials alone (usual care)
Number of subjects: 100
Study 11149624 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion (1.5 mU/kg x min)
Number of subjects: 50
Study 11149624 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (saline solution)
Number of subjects: 50
Study 8637693 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry with sterile disposable silicone tonometer shield
Number of subjects: 120
Study 8637693 — intervention group
Group type: COMPARATOR
Intervention: Goldmann applanation tonometry without shield (uncovered)
Number of subjects: 120
Study 8637693 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometry with silicone shield
Number of subjects: 120
Study 1483552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg/day
Number of subjects: 399
Study 1483552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 4048899 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 9
Study 4048899 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate tablets
Number of subjects: 9
Study 4048899 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-Mg-hydroxide tablets
Number of subjects: 9
Study 4048899 — intervention group
Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 9
Study 4048899 — intervention group
Group type: EXPERIMENTAL
Intervention: Magaldrate liquid
Number of subjects: 9
Study 4048899 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-Mg-hydroxide liquid
Number of subjects: 9
Study 30041895 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomic adjustment and physiotherapy program (using ErgoDis/IBV software) for twelve weeks, two 60-min sessions per week
Number of subjects: 8
Study 30104421 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse home visit after standard pediatric discharge
Number of subjects: 1372
Study 27063928 — intervention group
Group type: EXPERIMENTAL
Intervention: AZP-531 15 µg/kg or higher
Number of subjects: 112
Study 27063928 — intervention group
Group type: EXPERIMENTAL
Intervention: AZP-531
Number of subjects: 112
Study 27063928 — intervention group
Group type: EXPERIMENTAL
Intervention: AZP-531 60 µg/kg
Number of subjects: 112
Study 27063928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 24866968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic supportive‐expressive therapy
Number of subjects: 134
Study 24866968 — intervention group
Group type: COMPARATOR
Intervention: Supportive clinical management combined with pharmacotherapy or placebo
Number of subjects: 134
Study 23135193 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 week of rapid expansion followed by maxillary protraction (group A)
Number of subjects: 20
Study 23135193 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 weeks of repetitive rapid expansion and constriction followed by maxillary protraction (group B)
Number of subjects: 20
Study 20822968 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µg/m³ elemental carbon UFP for 2 hr
Number of subjects: 19
Study 20822968 — intervention group
Group type: COMPARATOR
Intervention: Filtered air
Number of subjects: 19
Study 17937474 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 to 10 mg/kg) plus methotrexate (MTX)
Number of subjects: 2495
Study 17937474 — intervention group
Group type: COMPARATOR
Intervention: MTX plus placebo
Number of subjects: 2495
Study 15848713 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 3209
Study 15848713 — intervention group
Group type: COMPARATOR
Intervention: No induction
Number of subjects: 3209
Study 11931675 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD group
Number of subjects: 34
Study 11931675 — intervention group
Group type: COMPARATOR
Intervention: NA control group
Number of subjects: 34
Study 11931675 — intervention group
Group type: COMPARATOR
Intervention: GAD group
Number of subjects: 34
Study 9767748 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectra Leukoreduction System (LRS)
Number of subjects: 115
Study 9767748 — intervention group
Group type: COMPARATOR
Intervention: Standard plateletpheresis procedures (control)
Number of subjects: 115
Study 9767748 — intervention group
Group type: EXPERIMENTAL
Intervention: LRS
Number of subjects: 115
Study 7610357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extract (Pancrex-Duo capsules, 34,375 USP units of protease, 4 capsules four times daily for 4 months)
Number of subjects: 26
Study 7610357 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 capsules four times daily for 4 months)
Number of subjects: 26
Study 7610357 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic extract and placebo (second 4 months of follow-up)
Number of subjects: 26
Study 2118307 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 320/1,600 mg daily
Number of subjects: 132
Study 2118307 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ) 160/800 mg daily
Number of subjects: 132
Study 2118307 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Number of subjects: 132
Study 2118307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin at a dose of 60 mg/m2
Number of subjects: 0
Study 215307 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymosin at a dose of 20 mg/m2
Number of subjects: 0
Study 215307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31133127 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (milk and eggs)
Number of subjects: 336
Study 31133127 — intervention group
Group type: COMPARATOR
Intervention: Control (basic food allowance)
Number of subjects: 336
Study 28618724 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 mg/BD/IM)
Number of subjects: 0
Study 24441390 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve sclerosis (AVS)
Number of subjects: 41
Study 24441390 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 41
Study 24441390 — intervention group
Group type: EXPERIMENTAL
Intervention: Culprit lesion Syntax score (SX score)
Number of subjects: 41
Study 24441390 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-to-balloon time
Number of subjects: 41
Study 24441390 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender, smoking, hypertension
Number of subjects: 41
Study 23588235 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactulose 25 g
Number of subjects: 43
Study 21810024 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 88
Study 21810024 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir
Number of subjects: 88
Study 19513632 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily (o.d.) dosing of insulin detemir
Number of subjects: 0
Study 19513632 — intervention group
Group type: COMPARATOR
Intervention: Twice daily (b.i.d.) dosing of insulin detemir
Number of subjects: 0
Study 19513632 — intervention group
Group type: COMPARATOR
Intervention: Switching from o.d. to b.i.d. dosing
Number of subjects: 0
Study 19513632 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 0
Study 16426286 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream containing vaseline
Number of subjects: 0
Study 16426286 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream containing bees wax
Number of subjects: 0
Study 16426286 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream containing waxes and surfactant
Number of subjects: 0
Study 16426286 — intervention group
Group type: COMPARATOR
Intervention: No barrier cream (control)
Number of subjects: 0
Study 12877903 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 5 mg/day for 4 weeks
Number of subjects: 24
Study 12877903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10764367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner consultations
Number of subjects: 1292
Study 10764367 — intervention group
Group type: COMPARATOR
Intervention: General Practitioner consultations
Number of subjects: 1292
Study 8818851 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg once daily for 3 days)
Number of subjects: 369
Study 8818851 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav (37 mg three times daily for 10 days)
Number of subjects: 369
Study 8818851 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 369
Study 8818851 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 369
Study 1444727 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 59
Study 1444727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 4063589 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital care
Number of subjects: 91
Study 4063589 — intervention group
Group type: COMPARATOR
Intervention: In‐patient care
Number of subjects: 91
Study 30957878 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent cartoon
Number of subjects: 3000
Study 30957878 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent cartoon
Number of subjects: 3000
Study 30957878 — intervention group
Group type: COMPARATOR
Intervention: Nonviolent cartoon (females)
Number of subjects: 3000
Study 30957878 — intervention group
Group type: EXPERIMENTAL
Intervention: Violent cartoon (males)
Number of subjects: 3000
Study 30957878 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediation analysis
Number of subjects: 3000
Study 29179601 — intervention group
Group type: EXPERIMENTAL
Intervention: Education based on health belief model (HBM)
Number of subjects: 60